TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03959540
Drug: Levodopa (L-DOPA) + Standard care
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa (immediate- or controlled-release) + Standard care. Use of Levodopa and standard of care are only driven by the physician's decision.
Study: NCT00003207
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01697527
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04242927
Drug: Routine care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routinely apply urea ointment and provide best supportive care.
Study: NCT00954369
Drug: [F-18]W372
Approvals — FDA: no, EMA: no, PMDA: no
Description: The individual doses of \[F-18\]W372 contain a maximum of 20 mCi for normal volunteers and 10 mCi for high probability AD subjects.~The single IP dose is administered to the study subject immediately prior to the start of PET imaging.
Study: NCT00446316
Drug: Antacids (Mg-Al-based)
Approvals — FDA: no, EMA: no, PMDA: no
Description: the antacid (Maximum Strength Maalox®Max® Antacid/Anti-gas) at a dose level of 20 mL (equivalent to 1600 mg aluminum hydroxide and 1600 mg magnesium hydroxide).
Study: NCT03119038
Drug: Bupivicaine + epinephrine
Normalized name: bupivacaine / epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine with epinephrine
Study: NCT03119038
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative periarticular injection of 30 mg
Study: NCT03206944
Drug: acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group 1(ASA) included 33 patients who received acetylsalicylic acid at a dose of 75 mg in the morning
Study: NCT02782455
Drug: CDobi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium dobesylate is administered
Study: NCT04429347
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Friday night: 1 capsule, Saturday night: 2 capsule, Sunday night: choice of 1 or 2 capsules
Study: NCT01158534
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT02887534
Drug: Placebo1401
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00820703
Drug: Nexagon®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00820703
Drug: Nexagon® vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02306772
Drug: TP05 Coating A
Approvals — FDA: no, EMA: no, PMDA: no
Description: One radio-labelled tablet given to subjects
Study: NCT02099916
Drug: Gonadotropins
Normalized name: GONADOTROPINS
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.
Study: NCT04116632
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT00869336
Drug: Placebo Comparator -2 wks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied daily for 2 weeks
Study: NCT00869336
Drug: Placebo Comparator - 4 wks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied daily for 4 weeks
Study: NCT01885195
Drug: MEK162
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEK162 will be dosed on a flat scale of 45 mg twice daily on a continuous dosing schedule.
Study: NCT02941107
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo for this trial will be Viscosweet, a clear and flavoured solution used as a pharmaceutical excipient repackaged into a labelled syringe identical to the active and firmly sealed with an end cap.
Study: NCT02647762
Drug: CF101 1 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF101 tablets, 1mg BID for 12 weeks
Study: NCT02647762
Drug: CF101 2 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF101 tablets, 2 mg BID for 12 weeks
Study: NCT03783429
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets will be given orally
Study: NCT02284906
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone placebo-matching tablets
Study: NCT01180374
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (about a quarter spoon of alcohol with no CBD).
Study: NCT01180374
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (about a quarter spoon of alcohol with no THC) given intravenously over 20 minutes.
Study: NCT01703819
Drug: Neurexan®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
Study: NCT00070200
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00070200
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02583789
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a sugar pill manufactured to resemble UT-15C. Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase
Study: NCT00860340
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg tablet of Spironolactone (Aldactone) by mouth with half a glass of water.
Study: NCT01975272
Drug: Placebo for ferinject
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00282165
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: four weeks double blind placebo treatment
Study: NCT01149278
Drug: maintain mean arterial pressure between 80-85 mm Hg
Normalized name: SUS SCROFA ARTERY
Approvals — FDA: no, EMA: no, PMDA: no
Description: protocolized hemodynamic care aiming to maintain mean arterial pressure between 80-85 mm Hg
Study: NCT01892254
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (to metformin)
Study: NCT00115830
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00446316
Drug: Imatimib Mesylate (Gleevec®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gleevec® will be administered at a dose of 400 mg. Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1. The other half will be treated in reverse order, i.e., they will receive the combination of Gleevec® and antacid on day 1, and Gleevec® alone on day 15. The antacids will be administered 15 minutes before the Gleevec® dose.
Study: NCT03511261
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 4 placebo capsules for oral intake two times per day
Study: NCT01938820
Drug: Thymosin-α
Normalized name: chymosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: antiviral and antifibrosis therapy
Study: NCT04585230
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roll- On stick with no CBD and no Mineral Oil
Study: NCT02869217
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01095250
Drug: AIN457
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01095250
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01323673
Drug: Vehicle / Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 times a day, 14 total days of study treatment
Study: NCT00783705
Drug: inositol
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT02429596
Drug: Experimental
Normalized name: WA-001 Experimental Soil Surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch from brand to generic
Study: NCT00758927
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered simultaneously with exercise and diet therapy in same intensity with the experimental arm
Study: NCT02775864
Drug: Antipsychotic
Normalized name: ANTIPSYCHOTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: New initiation of any antipsychotic medication
Study: NCT02775864
Drug: Antidepressant
Normalized name: Antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: New initiation of any antidepressant medications
Study: NCT02775864
Drug: Mood stabilizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: New initiation of lithium or any mood stabilizing anti-epileptic drug
Study: NCT03907488
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00934193
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment will consist of a 600 mg dose of gabapentin or placebo given preoperatively the night before surgery, based on a computer generated randomized assignment. The treatment group will continue to be medicated with gabapentin 300 mg twice daily for one month following surgery. Those not included in the treatment arm of the study will continue to take a placebo for the same duration. Follow-up will consist of a postoperative visit at approximately 48 hours and a one month clinical visit.
Study: NCT06736353
Drug: Beta Blocker Therapy or No Therapy (Control)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blocker therapy or no Beta blocker therapy initiated after type 2 myocardial infarction
Study: NCT06736353
Drug: RAAS blocker Therapy or No therapy (Control)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAAS blocker therapy or no RAAS blocker therapy initiated after type 2 myocardial infarction
Study: NCT06736353
Drug: Statin Therapy or No Therapy (Control)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy or no Statin therapy initiated after type 2 myocardial infarction
Study: NCT06736353
Drug: Single Antiplatelet Therapy or No Therapy (Control)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Antiplatelet Therapy or no antiplatelet therapy initiated after type 2 myocardial infarction
Study: NCT02826044
Drug: SP2086
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study has 3 doses groups and the 30 subjects were administrated SP2086 50mg,100mg,200mg respectively.
Study: NCT00763204
Drug: AN2728 Cream, 2%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00763204
Drug: AN2728 Cream, 1%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00763204
Drug: AN2728 Cream, 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00763204
Drug: Betnesol®-V Creme, 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03238235
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: suspension manufactured to mimic Givinostat
Study: NCT01280123
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will contain microcrystalline cellulose. An over-encapsulation process will be conducted in accordance with Clinical Good Manufacturing Procedures (cGMP) regulations to create a dosage form for the active study drug that will be indistinguishable from the comparator (Placebo) capsule.
Study: NCT02151409
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose (SD), administrated i.v. (intravenous) or s.c. (subcutaneously).
Study: NCT03844633
Drug: Depo-Provera Injectable Product
Normalized name: Depo-Provera Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depo-Provera Injectable Product -- Shot administered within 48 hours of childbirth
Study: NCT03844633
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos -- Shot administered within 48 hours of childbirth
Study: NCT03743064
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered as matching placebo tablets in the fasted condition)
Study: NCT02603848
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: (10mg/kg; maximum 600 mg) every six hours as needed
Study: NCT01011920
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) on day 1, every 3 weeks for a maximum of 4 courses.
Study: NCT02790515
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV infusion prior to transplant on Day -9.
Study: NCT01530607
Drug: Standard cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC (3 mos/4 cycles), CAF (6 mos/cycles), TAC (6 mos/cycles), CEF (6 mos/cycles) AC followed by taxane (6 mos/8 cycles), CMF (6 mos)
Study: NCT01741194
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken once daily, by mouth
Study: NCT00156546
Drug: antibiotic to reduce the recurrence of infection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02811484
Drug: Insulin Titration
Normalized name: INSULIN TITRATION ORAL INHL KIT 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal insulin titration up to 12 weeks followed by basal-bolus regimen in those with HbA1c\>8%
Study: NCT00715624
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.
Study: NCT01830153
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01044277
Drug: Gluthathione peroxidases
Normalized name: peroxidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg, two times daily
Study: NCT05431413
Drug: Control group: Fluoxetine and Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cap Fluoxetin 20mg OD for four weeks and injection 100ml normal saline(NS) BD for two weeks.
Study: NCT05431413
Drug: Experimental group: Fluoxetine and ATP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cap Fluoxetin 20mg OD for four weeks and injection ATP 100mg in NS BD for two weeks.
Study: NCT05431413
Drug: Control group: Fluoxetine and Phosphocreatine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cap Fluoxetin 20mg OD for four weeks and injection Phosphocreatine 1g in NS BD for two weeks.
Study: NCT04617613
Drug: Omeprazole, Amoxicillin, Metronidazole and Clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first group (standard triple therapy group) received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg. The second group (quadruple therapy group) received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg. Patients in both groups received omeprazole capsule twice daily before meals and the rest of the drugs twice daily after meals for 14 days.
Study: NCT04617613
Drug: Omeprazole, Amoxicillin and Clarithromycin
Normalized name: omeprazole, amoxicillin and clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first group (standard triple therapy group) received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg. The second group (quadruple therapy group) received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg. Patients in both groups received omeprazole capsule twice daily before meals and the rest of the drugs twice daily after meals for 14 days.
Study: NCT01791868
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo. All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the French Experts Recommendation 2009(RFE 2009).
Study: NCT03403504
Drug: OXYCONTIN®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered OXYCONTIN® Tablet 10 mg
Study: NCT00540722
Drug: R-(-)-gossypol acetic acid
Normalized name: citronellol acetate, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04224740
Drug: Standard of care therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciplastin 70mg/m² IV D1(or carboplatin AUC 5) plus 5-Fluouracil 1000mg/m²/day IV( continuous infusion on Days 1-4) Q3W for 6 cycles
Study: NCT01355068
Drug: Epanutin Infatabs (Phenytoin)
Normalized name: phenytoin sodium Oral Capsule [Epanutin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewable Tablet, 50 mg, Single dose
Study: NCT01724736
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celluose 10g - Matches the total dietary fiber content of NM504 as well as the color and taste. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
Study: NCT01724736
Drug: NM504:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobiotic formula of GRAS ingredients with a total dietary fiber content of 10g. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
Study: NCT02110810
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin suppository of 100 mg immediately afterwards while still under sedation
Study: NCT03712163
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02015598
Drug: Carbocysteine
Normalized name: Carbocysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: carbocisteine (2×250 mg, three times daily) for 6 weeks. The tablets are provided by Baiyunshan Pharmaceutical, China. patients will interviewed after 3 weeks to check their adherence to the study regimen by collecting and counting the number of remaining tablets, record adverse events, and refill study tablets for the next 3 weeks.
Study: NCT00256867
Drug: GSK523338
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00701740
Drug: oral isotretinoin and Mexoryl SX / XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg, 3/week,continuously for three months
Study: NCT00701740
Drug: Mexoryl XL / SX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11 subjects used only the same moisturizer and SPF 60 sunscreen
Study: NCT04020510
Drug: onaBoNT-A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradetrusor onabotulinumtoxinA in either the standard number of injections or a reduced number of injections
Study: NCT01675219
Drug: single immediate chemotherapy instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: single immediate post TUR-BT epirubicin (2mg/ml, total of 100 ml) instillation
Study: NCT03088293
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive prednisone and cyclophosphamide intravenously (700 mg/m2 every 4 weeks intravenously) (n=25) for 16 weeks.
Study: NCT04307147
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral capecitabine (at a dose of 1250 mg/m², twice per day, on days 1 to 14) every 3 weeks for 4 cycles.
Study: NCT00670202
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet manufactured to mimic fasudil three times a day x 14 days
Study: NCT02944799
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of alendronate treatment
Study: NCT02944799
Drug: Calcium
Normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dietary supplement of 800mg calcium
Study: NCT00998309
Drug: Azithromycin SR
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zithromax SR 2g, taking once for treatment.
Study: NCT02959710
Drug: AC-1202 mixed in Ensure®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g AC-1202 (shaken in approximately 8 oz \[237 mL of Ensure® Original\] at Hour 0 on Day 1)
Study: NCT04030715
Drug: bismuth-containing quadral therapy based on antibiotic susceptibility
Approvals — FDA: no, EMA: no, PMDA: no
Description: the different mucosal pathology graded by New Sydney System
Study: NCT01869985
Drug: HCP1104 / Mulex Tab. and Airtal Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCP1104 / Eperisone plus Aceclofenac
Study: NCT01173627
Drug: Test fentanyl citrate 400 mcg troche
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test fentanyl citrate 400 mcg troche administered as a single dose under fasted conditions
Study: NCT02429427
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 400mg of Celecoxib once daily for two years or until disease progression (if before the two years limit) or until development of unacceptable toxicities. In addition ER(+) patients will receive endocrine treatment according to local practice.
Study: NCT01307111
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pills which are identical to the study drug in appearance, taste, and smell.
Study: NCT02467478
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet daily for 12 weeks
Study: NCT00258128
Drug: Salsalate
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active
Study: NCT00258128
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for salslate, used only in the third trial
Study: NCT00931788
Drug: Antihypertensive agents and lipid lowering therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: The above agents will be initiated/titrated in accordance to guidelines approved by Canadian Hypertension Education Program and the Canadian Best Practice Recommendations for Stroke Care
Study: NCT00380354
Drug: GSK256066
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02431975
Drug: LPV/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir is an antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir.~LPV/r will be dosed as per standard guideline and routine practices.
Study: NCT01061268
Drug: No topical artificial tear
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 patients randomized to not using a topical artificial tear.
Study: NCT01061268
Drug: Blink® Tears Lubricant Eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blink® Tears Lubricant Eye Drops
Study: NCT01292226
Drug: corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to manufacturer recommendation